Key result
TIM-3 modulates immune responses in atherosclerosis, MI, and myocarditis depending on specific ligand interactions.
Why the study?
Immune checkpoints regulate immune responses in CVD, but the role of TIM-3 signaling and whether interfering with it can improve cardiovascular health requires further mechanistic research.
TIM-3 is a complex immune checkpoint that modulates immune reactions in cardiovascular diseases, highlighting a potential target for future mechanistic research.
Premature to target TIM-3 clinically in CVD; leaves open context- and ligand-specific effects for mechanistic research.
Immune checkpoints have come to light as potent regulators of immune responses in tumour biology, autoimmune disease and, more recently, in CVD. TIM-3 is a complex immune checkpoint expressed on both immune and non-immune cells. It has four known ligands, two of which are only available for binding upon cell damage or death, and binding can be either stimulatory or inhibitory. It functions as a context-dependent modulator of immune reactions in atherosclerosis, myocardial infarction and myocarditis. TIM-3 may exert functions in the cardiovascular system, but more mechanistic research is required to investigate whether interference with TIM-3 signalling can be used to improve cardiovascular health.
No takes yet. Share an insight, caveat, or question.
Yousif et al. (2026) conducted a review in Cardiovascular Disease. TIM-3 functions as a context-dependent modulator of immune reactions in atherosclerosis, myocardial infarction, and myocarditis, with its effects depending on specific ligand interactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: